Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Weight Loss × Tirzepatide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Obesity 8 Endometrial Neoplasms 4 Prostatic Neoplasms 2 Endometrial Hyperplasia 2 Diabetes Mellitus 2 Breast Neoplasms 2 Weight Loss 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Overweight 1 Opioid-Related Disorders 1 Metabolic Syndrome 1 Lymphoma, Follicular 1 Insulin Resistance 1 Inflammation 1 Hyperplasia 1 Dyslipidemias 1 Colorectal Neoplasms 1

Interventions

Exercise 8 Diet 5 Caloric Restriction 5 Metformin 4 Octreotide 3 Nutrition Assessment 3 Megestrol Acetate 3 Cognitive Behavioral Therapy 3 anamorelin 2 Standard of Care 2 Olanzapine 2 Liraglutide 2 Eicosapentaenoic Acid 2 Diet, Carbohydrate-Restricted 2 Diet Therapy 2 sibutramine 1 remune 1 olanzapine-fluoxetine combination 1 lime 1 irinotecan sucrosofate 1 bermekimab 1 Weight Reduction Programs 1 Urine Specimen Collection 1 Tirzepatide 1 Surveys and Questionnaires 1 Sugars 1 Sampling Studies 1 Ritonavir 1 Resistance Training 1 Quality of Life 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06518837 2026-01-21

FITWISE

Rutgers, The State University of New Jersey

Phase 2 Recruiting

Weight Loss

Data powered by HemOnc (CC BY 4.0) Colophon ⚡